Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001437749-24-026903

CMO & Sr VP, Clinical Dev. acquired 12,800 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Huhn Stephen L. · CMO & Sr VP, Clinical Dev.

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-08-13 Exercise or conversion : show line 1 in the form +12,800 $1.01 $12,928 12,800 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-08-13 Exercise or conversion : show line 2 in the form Stock Option (right to buy) −12,800 161,394 D
Loading xslF345X05/rdgdoc.xml…